15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Avalo Therapeutics Inc, 11 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $34.00 to $60.00, a moderate spread. The average target of $45.80 sits 135% above the current $19.51. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 11 over recent months. On the fundamentals, the Street sees revenue growth near -100% this year and 0% next, consensus EPS building from about $-0.55 next quarter toward $-2.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy11100%
Hold00%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Avalo Therapeutics Inc.
As of Jul, 11 of 11 firms rate AVTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AVTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.55
Range $-0.84 – $-0.27 · 10 analysts · -75% YoY
Next period, 10 analysts expect Avalo Therapeutics Inc to earn $-0.55 a share (range $-0.84 – $-0.27), versus $-2.19 a year earlier. Full-year consensus is $-2.56, growing to $-2.76 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 10 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Avalo Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVTX.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$55.00+181.9% to target
Overall win rate
57%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #28
Buy
$50.00+156.3% to target
Overall win rate
52%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$60.00+207.5% to target
Overall win rate
34%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$35.00+79.4% to target
Overall win rate
34%
+ Follow
#5
EW
Edward White
HC Wainwright & Co. · Rank #241
Hold
No targeton AVTX
Overall win rate
31%
+ Follow
AVTX stock forecast FAQ
What is AVTX's average 12-month price target?+
The 10 analysts with a live target average $45.80 for Avalo Therapeutics Inc over the next 12 months, ranging from a $60.00 high to a $34.00 low.
Is AVTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 11 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AVTX?+
The Street-high target is $60.00 (Piper Sandler), and the Street-low is $34.00 (Wedbush). The average of all 10 active targets is $45.80.
How many Wall Street analysts cover AVTX?+
11 analysts have an active rating on Avalo Therapeutics Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering AVTX?+
Among analysts who currently cover AVTX, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $55.00 target.
What is Avalo Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.55 per share (range $-0.84 – $-0.27) across 10 analysts. Full-year EPS is projected at $-2.56, rising to $-2.76 the following year.
How much revenue is Avalo Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading AVTX lately?+
As of Jul, 11 of 11 firms rate AVTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
